Stargardt Disease Clinical Trials

16 studies are recruiting for stargardt disease in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Study of ALK-001 on the Progression of Stargardt Disease

   This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (STGD)

   Stage

   Phase 3

   Ages

   8 to 45

   Site

   Associated Retina Consultants, Phoenix, Arizona

   Locations

   14 in total

   Run by

   Alkeus Pharmaceuticals, Inc.

   See if you can join NCT07419334 on ClinicalTrials.gov

2. The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration

   Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner retina. The investigator will aim to evaluate the impact of oral disulfiram…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Flaum Eye Institute, University of Rochester Medical Center, Rochester, New York

   Run by

   University of Rochester

   See if you can join NCT06319872 on ClinicalTrials.gov

3. A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions

   Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye. In people with macular dystrophies, some of the cells in the macula gradually stop working and may die over time. This lead…

   Stage

   Phase 1

   Ages

   6 and older

   Site

   Associated Retina Consultants, Phoenix, Arizona

   Locations

   3 in total

   Run by

   Astellas Institute for Regenerative Medicine

   See if you can join NCT07734064 on ClinicalTrials.gov

4. A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults

   Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye. In people with macular dystrophies, some of the cells in the macula gradually stop working and may die over time. This lead…

   Stage

   Not phased

   Ages

   6 and older

   Site

   Associated Retina Consultants, Phoenix, Arizona

   Locations

   15 in total

   Run by

   Astellas Pharma Global Development, Inc.

   See if you can join NCT07425574 on ClinicalTrials.gov

5. Phase 1 Study of C.001 in Retinal Degeneration

   This is a first-in-human Phase 1 study evaluating the safety and tolerability of C.001 in patients with retinal diseases involving degeneration of the retinal pigment epithelium. Participants will receive a single administration of C.001 delivered by subretinal injection. The study will evaluate th…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Retina Vision Consultants, Beverly Hills, California

   Locations

   3 in total

   Run by

   Cellio Therapeutics Inc

   See if you can join NCT07594236 on ClinicalTrials.gov

6. A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

   The purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a biallelic mutation of the ABCA4 gene. The study will also assess initial efficacy following AAVB-039 administration.

   Stage

   Phase 1

   Ages

   8 to 55

   Site

   Associated Retina Consultants, Phoenix, Arizona

   Locations

   9 in total

   Run by

   AAVantgarde Bio Srl

   See if you can join NCT07161544 on ClinicalTrials.gov

7. Stem Cell Ophthalmology Treatment Study II

   This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.

   Stage

   Not phased

   Ages

   18 and older

   Site

   MD Stem Cells, Westport, Connecticut

   Locations

   4 in total

   Run by

   MD Stem Cells

   See if you can join NCT03011541 on ClinicalTrials.gov

8. Inherited Retinal Degenerative Disease Registry

   The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by the Foundation. It is a patient-initiated registry accessible via a secure on-line portal at www.MyRetinaTracker.org. Af…

   Stage

   Not phased

   Ages

   Any age

   Site

   Foundation Fighting Blindness, Columbia, Maryland

   Run by

   Foundation Fighting Blindness

   See if you can join NCT02435940 on ClinicalTrials.gov

9. Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease

   A Phase 1/2, open-label, non-randomized, dose-escalation study, where a minimum of 9 and a maximum of 18 eligible patients with Stargardt Disease will be enrolled sequentially in up to 3 dose cohorts of RTx-021. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-021 i…

   Stage

   Phase 1

   Ages

   16 and older

   Site

   RayTx Clinical Site, Bakersfield, California

   Locations

   3 in total

   Run by

   Ray Therapeutics, Inc.

   See if you can join NCT07439887 on ClinicalTrials.gov

10. Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

    The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment. The …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Vision Research and Assessment Institute, Irvine, California

    Run by

    Ray Therapeutics, Inc.

    See if you can join NCT07502664 on ClinicalTrials.gov

11. Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

    This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.

    Stage

    Not phased

    Ages

    5 and older

    Site

    University of San Francisco, San Francisco, California

    Locations

    8 in total

    Run by

    Ascidian Therapeutics, Inc

    See if you can join NCT06445322 on ClinicalTrials.gov

12. Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

    This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    University of San Francisco, San Francisco, California

    Locations

    10 in total

    Run by

    Ascidian Therapeutics, Inc

    See if you can join NCT06467344 on ClinicalTrials.gov

13. An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

    This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene This is a multicenter study which will enroll approximately 75 subjects

    Stage

    Not phased

    Ages

    12 to 65

    Site

    Shiley Eye Institute, San Diego, California

    Locations

    20 in total

    Run by

    Splice Bio

    See if you can join NCT06435000 on ClinicalTrials.gov

14. A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

    This Phase 1/2 study will evaluate the safety, tolerability, and preliminary efficacy of subretinal SB-007 administration to determine dose selection in subjects with Stargardt's Type 1 (STGD1). This is a multicenter study which will enroll approximately 57 subjects, followed up over a 96 week peri…

    Stage

    Phase 1

    Ages

    12 to 65

    Site

    UCHealth Sue Anschutz-Rodgers Eye Center,, Aurora, Colorado

    Locations

    5 in total

    Run by

    Splice Bio

    See if you can join NCT06942572 on ClinicalTrials.gov

15. A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT

    The goal of this observational study is to assess the reliability and validity of the 9-object MLSDT for evaluation of participants with moderate to severe vision impairment when tested without a wearable low-vision magnifying aid (eGlasses) and then with eGlasses. These results will be compared to…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Retina of North Texas,, Dallas, Texas

    Run by

    Nanoscope Therapeutics Inc.

    See if you can join NCT06805474 on ClinicalTrials.gov

16. Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration

    The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment. The …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Vision Research and Assessment Institute, Irvine, California

    Run by

    Ray Therapeutics, Inc.

    See if you can join NCT06375239 on ClinicalTrials.gov